Clinical trials show that slow dose escalation reduces adverse event severity by 40-50% compared to rapid initiation protocols
One aspect of it is that only about 40 percent of people are on medications after a year, and we dont know why, continues Holst
T1D Fund portfolio company i2O Therapeutics is developing several products leveraging GLP-1s, initially for T2D, including a refillable, implantable GLP-1 device that delivers 6 months worth of the hormone, an oral form of long acting GLP-1, as well as a combined oral GLP-1 with Amylin (another important pancreatic hormone)
, , -:
Recent research has shown that sickle cell trait-positive whole blood and Power Red donations do not adequately pass a quality control step due to a filter limitation during processing
Agrawal M, Pradhan M, Singhvi G, Patel R, Alexander A, Alexander A